Don R Pearson

US Patent:

6359007, Mar 19, 2002

Filed:

Mar 23, 2000

Appl. No.:

09/534909

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

ChronoRX, LLC - Anchorage AK

International Classification:

A61K 31195

US Classification:

514565

Abstract:

Various clinical uses for L-arginine complexes are presented. The active agents have individual and complementary physiological functions especially as these relate to conditions and functions, which influence endothelial biochemistry and physiology. The active components of the invention are selected for inclusion in unique combinations that will clinically reduce risks of vasculopathy in various diseases. The reduction of endothelial dysfunctional risks, often associated with aging and generalized poor vascular health and function, will maximize the potential clinical therapeutic success of other mediations and concurrently avoid some risks of pharmaceutical side effects.

US Patent:

6423847, Jul 23, 2002

Filed:

Mar 20, 2000

Appl. No.:

09/532658

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, LLC - Anchorage AK

International Classification:

C07D40500

US Classification:

5462827, 514337

Abstract:

A process of synthesis of D,-tocopherol nicotinate compounds is presented. Therapeutic uses for this compound are described. The active agents are demonstrated to be complementary in their physiological functions especially as these relate to cellular and endothelial biochemistry and physiology and, ultimately to vascular health. The active components of the invention are selected for inclusion in a unique combination that clinically reduces risks of vasculopathy, DNA strand breakage and neuronal excitotoxicity in various diseases. In addition to the systemic vascular benefits acquired, improvement of the vascular health of the eye reduces the risk of glaucomatous optic nerve atrophy with its accompanying visual field loss and potential blindness and reduces conditions of risk for macular degeneration.

US Patent:

6429219, Aug 6, 2002

Filed:

May 3, 2000

Appl. No.:

09/564070

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, LLC - Anchorage AK

International Classification:

A61K 31425

US Classification:

514369, 514494, 514499, 514578

Abstract:

This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.

US Patent:

6524619, Feb 25, 2003

Filed:

Jan 19, 2001

Appl. No.:

09/765974

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, Inc. - Anchorage AK

International Classification:

A61K 920

US Classification:

424472, 424464, 424468

Abstract:

The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIII nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIII nerve atrophy, and the hearing loss and possible deafness that accompany them.

US Patent:

6531608, Mar 11, 2003

Filed:

Jun 11, 2002

Appl. No.:

10/167630

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, LLC. - Anchorage AK

International Classification:

C07D27702

US Classification:

548182, 556 45, 556110, 556118, 562557

Abstract:

This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.

US Patent:

6693094, Feb 17, 2004

Filed:

Mar 7, 2002

Appl. No.:

10/093476

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chrono RX LLC - Anchorage AK

International Classification:

A61K 31555

US Classification:

514188, 51425506, 514456, 514458, 514494, 514505, 514565, 514593, 514635

Abstract:

The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and/or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and/or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

US Patent:

6288106, Sep 11, 2001

Filed:

May 3, 2000

Appl. No.:

9/564074

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

ChronoRX, LLC - Anchorage AK

International Classification:

A61K 31385
C07D33902

US Classification:

514440

Abstract:

This invention is in the fields of pharmacology and biochemistry. It relates to processes for the synthesis of certain complexes of. alpha. -lipoic acid and the nutritional or therapeutic use of these and other related individual or complexed antioxidant, proglutathione molecules. Therapeutic uses for these molecules and complexes in the clinical management of conditions and functions associated with chronic glaucoma, insulin resistance, macular degeneration, lenticular cataract, neurodegenerative diseases, essential hypertension, atherosclerosis and vasoconstriction are described in particular.